TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07227285: Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Sponsor: Cyllene Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$761,940

Rescue Site Savings

+$507,960

Unlock Full NCT07227285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227285 Rescue Dossier →